Meeting Banner
Abstract #2216

Combining Data from HR MAS MR Spectroscopy and Gene Expression Can Refine the Subclassification of Breast Cancer

Eldrid Borgan1, Beathe Sitter2, Tone Frost Bathen2, Steinar Lundgren2,3, Hilde Johnsen1, Ole Christian Lingjrde4, Therese Srlie1,4, Anne-Lise Brresen-Dale1,5, Ingrid Susann Gribbestad2

1Department of Genetics, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway; 2Department of Circulation and Imaging, NTNU, Trondheim, Norway; 3Deptartment of Oncology, St. Olavs University Hospital, Trondheim, Norway; 4Department of Informatics, University of Oslo, Oslo, Norway; 5Faculty division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway

Joint analysis of gene expression microarrays and HR MAS metabolic profiles reveals differences within the luminal A tumors, a gene expression-based subtype of breast cancer. The luminal A subgroup is the largest and is associated with positive ER status and relatively good prognosis. However, a certain fraction of patients with luminal A breast cancer have a poor outcome. Preliminary results of 29 tumors from breast cancer patients show that differences in biochemistry and gene expression for two subgroups of luminal A tumors, identified by their metabolic MR profiles, are connected to lipid content and apoptosis.